Confidence is high for P2B Woldanorf.
Not only because P2 DMD results were so good and the FDA endpoints would easily be met today based on P2 results....but we also have data for ATL1102 from previous MS P2 study.
The MOA is now well understood - the efficacy at molecular level was clear and tangible as measured by PUL and FF%.
It's taken 20 years for ANP to be an overnight success
Question now is: will Sarepta or Pfizer want to be involved in a combination therapy trial?
.
One Study Away, page-3
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
